Based in Pittsburgh, Pennsylvania, the Center for Urological Regional Entrepreneurship (also known as CURE) is a nonprofit organization funded by the Heinz Endowments.

Its mission is to "steward the basic science research discoveries from the time they leave the laboratory to the time when the company resources can fund future investigation with the ultimate goal of successful clinical application". CURE is interested in compelling yet underdeveloped ides in the field of urology. The funding received from the Heinz Endowments through CURE is a significant catalyst for advancing ideas, bringing new treatments to the Urologic arena while contributing to the economic development of the Pittsburgh region.

Currently, there are three technologies under development:

Cook Myosite Inc has begun clinical trials of autologous
muscle-derived stem cells for treating stress urinary incontinence.
These cells have the ability to not only improve the function of the
muscles responsible for urinary continence but are believed to have
properties that may benefit erectile functioning as well. The first
clinical trial was successfully at the University of Toronto and a
second multicenter study is underway in Canada.

Lipella Pharmaceutical is currently in the preclinical phase in the
development of intravesical liposome treatment for irritable bladder
symptoms. There is not an established treatment approach for those
who suffer with this condition and by harnessing the properties of
liposomes to coat the bladder lining it is hoped that this will be a
viable treatment option for the 1 million Americans who suffer.

Delithe Natural Products Inc has introduced prolasta a product
of its kind shown to give men more time before ejaculation. By
understanding the science found within natural dietary supplements,
extracting the active ingredient and coupling it with advanced drug
delivery, a rapid release on demand tablet for men is offering a
natural choice for men who wish to extend their time during sexual intercource.

The effect of Prolasta may be similar to that of dapoxetine. The effects of hyperforin extract of Hypericum perforatum (prolasta's active ingredient, has been evaluated on the ejaculatory reflex duration by using the intravaginal ejaculatory latency time (IELT) and sexual satisfaction (Cannon-Smith and Kaufman, 2007). In this trial sixteen men who desired longer sexual intercourse and without erectile dysfunction took with hypferforin immediately prior to sexual activity. All 16 participants completed the trial and there was a significant increase in mean ejaculation times from 246±29 to 331±34 seconds (p<0.002) in persons taking the hyperforin extract prolasta. The increase was seen in both the men who reported PE as bothersome and those who did not feel that PE was a problem for them.

References

Cannon-Smith, T. W., Kaufman, J.H.: Improved Ejacultory Control And Sexual Satisfaction In Pilot Study Of Men Taking Hypericum Perforatum Extract . The Internet Journal of Nutrition and Wellness. 2007. Volume 3 Number 2.

External links

CURE.html/ The CURE website

The Heinz Endowments website

CookMyosite web site

Lipella Pharmaceutical website

Prolasta Website